Super Micro Computer Inc vs Tango Therapeutics Inc. — how do they compare? Super Micro Computer Inc trades at $34.96 (market cap $25.67B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Super Micro Computer Inc is far larger — about 6.8× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Super Micro Computer Inc for 20 Days and Tango Therapeutics Inc. for 0 Days on average.
| SMCI | TNGX | |
|---|---|---|
Market Cap | $25.67B | $3.75B |
Volume | 24,555,322 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $55.04 | $32.90 |
52-Week Low | $20.53 | $7.50 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $31.13B | $2.77B |
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $39.07, down 2.28% today, with a bullish technical signal and strong fundamental growth. The stock shows robust earnings beats, with Q2 2026 EPS of $1.70 exceeding the $0.923 estimate, and revenue is projected to grow from $22.0B in 2025 to $39.1B in 2026. Analyst consensus is a $42.33 price target, with 36% buy ratings. Recent news highlights AI-driven order surges and new NVIDIA Vera Rubin shipments, supporting positive sentiment amid competitive pressures.
The outlook for SMCI is positive, driven by AI infrastructure demand and earnings momentum, but risks include margin pressure and a Department of Justice investigation. Valuation remains attractive with a P/E of 11.98, though debt levels and market volatility warrant caution. Upside potential exists if the company maintains its growth trajectory and navigates legal challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →